The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.
 
Jin Won Kim
No Relationships to Disclose
 
Kyung-Hun Lee
No Relationships to Disclose
 
Ji-Won Kim
No Relationships to Disclose
 
Koung Jin Suh
No Relationships to Disclose
 
Ju-Hee Bang
No Relationships to Disclose
 
Yung-Jue Bang
Consulting or Advisory Role - BeiGene; Samyang
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca